GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190332020 | Oral cavity | OSCC | regulation of protein modification by small protein conjugation or removal | 165/7305 | 242/18723 | 2.52e-20 | 3.99e-18 | 165 |
GO:190305020 | Oral cavity | OSCC | regulation of proteolysis involved in cellular protein catabolic process | 152/7305 | 221/18723 | 2.16e-19 | 3.15e-17 | 152 |
GO:006113620 | Oral cavity | OSCC | regulation of proteasomal protein catabolic process | 132/7305 | 187/18723 | 1.57e-18 | 1.81e-16 | 132 |
GO:004325420 | Oral cavity | OSCC | regulation of protein-containing complex assembly | 255/7305 | 428/18723 | 2.94e-18 | 3.15e-16 | 255 |
GO:200005820 | Oral cavity | OSCC | regulation of ubiquitin-dependent protein catabolic process | 118/7305 | 164/18723 | 9.37e-18 | 9.27e-16 | 118 |
GO:003139620 | Oral cavity | OSCC | regulation of protein ubiquitination | 143/7305 | 210/18723 | 1.01e-17 | 9.80e-16 | 143 |
GO:003243420 | Oral cavity | OSCC | regulation of proteasomal ubiquitin-dependent protein catabolic process | 100/7305 | 134/18723 | 4.72e-17 | 4.04e-15 | 100 |
GO:006219720 | Oral cavity | OSCC | cellular response to chemical stress | 204/7305 | 337/18723 | 6.89e-16 | 5.19e-14 | 204 |
GO:004573220 | Oral cavity | OSCC | positive regulation of protein catabolic process | 150/7305 | 231/18723 | 1.06e-15 | 7.64e-14 | 150 |
GO:003133420 | Oral cavity | OSCC | positive regulation of protein-containing complex assembly | 153/7305 | 237/18723 | 1.18e-15 | 8.33e-14 | 153 |
GO:200123510 | Oral cavity | OSCC | positive regulation of apoptotic signaling pathway | 92/7305 | 126/18723 | 8.45e-15 | 5.19e-13 | 92 |
GO:000030220 | Oral cavity | OSCC | response to reactive oxygen species | 143/7305 | 222/18723 | 1.32e-14 | 7.88e-13 | 143 |
GO:190336420 | Oral cavity | OSCC | positive regulation of cellular protein catabolic process | 106/7305 | 155/18723 | 1.07e-13 | 5.53e-12 | 106 |
GO:003459920 | Oral cavity | OSCC | cellular response to oxidative stress | 173/7305 | 288/18723 | 2.90e-13 | 1.43e-11 | 173 |
GO:190180018 | Oral cavity | OSCC | positive regulation of proteasomal protein catabolic process | 82/7305 | 114/18723 | 9.33e-13 | 4.22e-11 | 82 |
GO:190305217 | Oral cavity | OSCC | positive regulation of proteolysis involved in cellular protein catabolic process | 92/7305 | 133/18723 | 1.60e-12 | 6.90e-11 | 92 |
GO:000756818 | Oral cavity | OSCC | aging | 194/7305 | 339/18723 | 6.18e-12 | 2.33e-10 | 194 |
GO:003243619 | Oral cavity | OSCC | positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 66/7305 | 90/18723 | 3.76e-11 | 1.23e-09 | 66 |
GO:200006020 | Oral cavity | OSCC | positive regulation of ubiquitin-dependent protein catabolic process | 75/7305 | 107/18723 | 6.67e-11 | 2.06e-09 | 75 |
GO:19033227 | Oral cavity | OSCC | positive regulation of protein modification by small protein conjugation or removal | 88/7305 | 138/18723 | 3.24e-09 | 7.39e-08 | 88 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0414122 | Liver | HCC | Protein processing in endoplasmic reticulum | 146/4020 | 174/8465 | 7.34e-24 | 2.46e-21 | 1.37e-21 | 146 |
hsa0501222 | Liver | HCC | Parkinson disease | 198/4020 | 266/8465 | 9.40e-20 | 1.58e-17 | 8.76e-18 | 198 |
hsa0501622 | Liver | HCC | Huntington disease | 219/4020 | 306/8465 | 3.06e-18 | 3.42e-16 | 1.90e-16 | 219 |
hsa0520842 | Liver | HCC | Chemical carcinogenesis - reactive oxygen species | 167/4020 | 223/8465 | 2.85e-17 | 1.91e-15 | 1.06e-15 | 167 |
hsa0493242 | Liver | HCC | Non-alcoholic fatty liver disease | 124/4020 | 155/8465 | 4.54e-17 | 2.54e-15 | 1.41e-15 | 124 |
hsa0502022 | Liver | HCC | Prion disease | 195/4020 | 273/8465 | 3.26e-16 | 1.56e-14 | 8.67e-15 | 195 |
hsa0541522 | Liver | HCC | Diabetic cardiomyopathy | 151/4020 | 203/8465 | 2.72e-15 | 1.01e-13 | 5.63e-14 | 151 |
hsa0513242 | Liver | HCC | Salmonella infection | 178/4020 | 249/8465 | 5.90e-15 | 1.98e-13 | 1.10e-13 | 178 |
hsa0517142 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
hsa0501022 | Liver | HCC | Alzheimer disease | 254/4020 | 384/8465 | 3.75e-14 | 8.97e-13 | 4.99e-13 | 254 |
hsa0502222 | Liver | HCC | Pathways of neurodegeneration - multiple diseases | 298/4020 | 476/8465 | 6.59e-12 | 1.30e-10 | 7.22e-11 | 298 |
hsa0414021 | Liver | HCC | Autophagy - animal | 99/4020 | 141/8465 | 3.08e-08 | 4.70e-07 | 2.61e-07 | 99 |
hsa0521022 | Liver | HCC | Colorectal cancer | 65/4020 | 86/8465 | 8.85e-08 | 1.23e-06 | 6.87e-07 | 65 |
hsa0491041 | Liver | HCC | Insulin signaling pathway | 95/4020 | 137/8465 | 1.53e-07 | 1.97e-06 | 1.10e-06 | 95 |
hsa0513042 | Liver | HCC | Pathogenic Escherichia coli infection | 129/4020 | 197/8465 | 2.02e-07 | 2.50e-06 | 1.39e-06 | 129 |
hsa0493121 | Liver | HCC | Insulin resistance | 77/4020 | 108/8465 | 3.89e-07 | 4.46e-06 | 2.48e-06 | 77 |
hsa0513542 | Liver | HCC | Yersinia infection | 92/4020 | 137/8465 | 2.25e-06 | 2.19e-05 | 1.22e-05 | 92 |
hsa0453042 | Liver | HCC | Tight junction | 110/4020 | 169/8465 | 2.45e-06 | 2.28e-05 | 1.27e-05 | 110 |
hsa0516921 | Liver | HCC | Epstein-Barr virus infection | 128/4020 | 202/8465 | 3.17e-06 | 2.79e-05 | 1.55e-05 | 128 |
hsa0516622 | Liver | HCC | Human T-cell leukemia virus 1 infection | 139/4020 | 222/8465 | 3.17e-06 | 2.79e-05 | 1.55e-05 | 139 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAPK9 | SNV | Missense_Mutation | novel | c.523A>T | p.Thr175Ser | p.T175S | P45984 | protein_coding | tolerated(0.5) | benign(0.001) | TCGA-AN-A0FL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAPK9 | insertion | In_Frame_Ins | novel | c.944_945insATCTATTCTGTGCCATTGGCTTTGGTTACATCC | p.Ala315_Leu316insSerIleLeuCysHisTrpLeuTrpLeuHisPro | p.A315_L316insSILCHWLWLHP | P45984 | protein_coding | | | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAPK9 | insertion | In_Frame_Ins | novel | c.521_522insTGTTCACAGGCACTTCTTGTTTCTGGTTTTTTGTTT | p.Arg174_Thr175insValHisArgHisPheLeuPheLeuValPheCysLeu | p.R174_T175insVHRHFLFLVFCL | P45984 | protein_coding | | | TCGA-AN-A0FL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAPK9 | SNV | Missense_Mutation | | c.196N>T | p.His66Tyr | p.H66Y | P45984 | protein_coding | deleterious(0.02) | possibly_damaging(0.672) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
MAPK9 | SNV | Missense_Mutation | | c.877N>G | p.Gln293Glu | p.Q293E | P45984 | protein_coding | tolerated(0.22) | benign(0.103) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MAPK9 | SNV | Missense_Mutation | | c.373N>T | p.His125Tyr | p.H125Y | P45984 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-UC-A7PF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
MAPK9 | SNV | Missense_Mutation | novel | c.1190C>T | p.Ser397Leu | p.S397L | P45984 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.879) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MAPK9 | SNV | Missense_Mutation | novel | c.715G>A | p.Glu239Lys | p.E239K | P45984 | protein_coding | tolerated(0.33) | benign(0.152) | TCGA-AA-3930-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | capecitabine | PD |
MAPK9 | SNV | Missense_Mutation | novel | c.752N>C | p.Lys251Thr | p.K251T | P45984 | protein_coding | deleterious(0) | possibly_damaging(0.897) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAPK9 | SNV | Missense_Mutation | | c.1078G>C | p.Val360Leu | p.V360L | P45984 | protein_coding | deleterious(0.04) | benign(0.011) | TCGA-AA-A02F-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | folinic | PR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5601 | MAPK9 | KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | | CAMPTOTHECIN | CAMPTOTHECIN | 10839298 |
5601 | MAPK9 | KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | | PMID25991433-Compound-P4 | | |
5601 | MAPK9 | KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | inhibitor | 178102618 | | |
5601 | MAPK9 | KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | | AG-1879 | CHEMBL406845 | |
5601 | MAPK9 | KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | | OSI-632 | OSI-632 | |
5601 | MAPK9 | KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | inhibitor | 178101956 | | |
5601 | MAPK9 | KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | | PD-0166285 | PD-0166285 | |
5601 | MAPK9 | KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | | SB-220025 | SB-220025 | |
5601 | MAPK9 | KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | | PMID25991433-Compound-O3 | | |
5601 | MAPK9 | KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | inhibitor | 223366077 | RGB-286638 | |